From: Annexin A1 in plasma from patients with bronchial asthma: its association with lung function
Characteristic | Control subjects | Asthmatic patients | ||
---|---|---|---|---|
Stable | Exacerbated | |||
No of subjects | 25 | 50 | ||
Sex (male/female) | 2/23 | 20/30 | ||
Age (of initial visit), yr | 58.3 ± 6.2 | 54.9 ± 14.1 | ||
Onset of asthma: age, yr | 47.06 ± 17.25 | |||
Asthma duration, yr | 6.63 ± 3.60 | |||
Smoking status (NS/ES/CS) | 25/0/0 | 32/12/6 | ||
Cigarettes smoked, pack. yr | 9.0 ± 15.7 | |||
Body Mass Index, kg/ m2 | 24.8 ± 2.61 | 25.4 ± 3.31 | ||
Stable and exacerbate lung function | FEV1, % pred. | 115.36 ± 16.59 | 85.43 ± 19.82 | 62.60 ± 18.14† |
FVC, % pred. | 96.56 ± 14.51 | 84.83 ± 16.68 | 66.51 ± 16.76† | |
FEV1 /FVC | 84.24 ± 6.05 | 74.53 ± 9.72 | 68.07 ± 11.84† | |
PC20, mg/ml | 9.18 ± 10.37 | |||
Total IgE, kU | 106.63 ± 188.7 | 421.5 ± 699.19* | ||
Atopy | 1 (4%) | 21 (42%)* | ||
Attack average/yr | 3.38 ± 3.24 | |||
Duration of exacerbation during follow up | 6.63 ± 3.61 | |||
Blood WBC/uL | 5587.2 ± 1268.0 | 7768.8 ± 3448.9* | 9873.0 ± 4917.1 | |
Blood eosinophil, % | 2.73 ± 2.26 | 5.09 ± 4.97* | 3.83 ± 5.42 | |
Blood neutrophil, % | 56.25 ± 9.8 | 54.7 ± 12.9 | 64.6 ± 19.3† |